Transient receptor potential vanilloid type 1 antagonists: A patent review (2011-2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 3, 2015, Pages 291-318

  Lee, Yoonji ^a   Hong, Sunhye ^a   Cui, Minghua ^a   Sharma, Pankaz K ^a   Lee, Jeewoo ^b   Choi, Sun ^a  

^a Ewha Womans University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Capsaicin; Transient receptor potential; TRPV1; TRPV1 antagonist; Vanilloid; VR1; VR1 antagonist

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; AZD 1386; DWP 05195; GRC 6211; GSK 2798745; JTS 653; MAVATREP; MK 2295; MR 1817; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; PAC 14028; PHE 377; SYL 1001; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; XEN D 0501; ANALGESIC AGENT; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATENT; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG DESIGN;

ANALGESICS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; TRPV CATION CHANNELS;

EID: 84922832432     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1008449     Document Type: Review

References (104)

1. Palazzo E, Luongo L, de Novellis V, et al. Transient receptor potential vanilloid type 1 and pain development. Curr Opin Pharmacol 2012;12:9-17
2. Szolcsanyi J, Sandor Z. Multisteric TRPV1 nocisensor: a target for analgesics. Trends Pharmacol Sci 2012;33:646-55
3. Conway SJ. TRPing the switch on pain: an introduction to the chemistry and biology of capsaicin and TRPV1. Chem Soc Rev 2008;37:1530-45
4. Palazzo E, Rossi F, de Novellis V, et al. Endogenous modulators of TRP channels. Curr Top Med Chem 2013;13:398-407
5. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999;51:159-211
6. Latorre R, Brauchi S, Orta G, et al. ThermoTRP channels as modular proteins with allosteric gating. Cell Calcium 2007;42:427-38
7. Liao M, Cao E, Julius D, et al. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature 2013;504:107-12
8. Cao E, Liao M, Cheng Y, et al. TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 2013;504:113-18 bound with vanilloid ligands.
9. Tominaga M, Tominaga T. Structure and function of TRPV1. Pflugers Arch 2005;451:143-50
10. Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007;6:357-72
11. Ferrer-Montiel A, Garcia-Martinez C, Morenilla-Palao C, et al. Molecular architecture of the vanilloid receptor. Insights for drug design. Eur J Biochem 2004;271:1820-6
12. Lee JH, Lee Y, Ryu H, et al. Structural insights into transient receptor potential vanilloid type 1 (TRPV1) from homology modeling, flexible docking, and mutational studies. J Comput Aided Mol Des 2011;25:317-27
13. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev 2009;60:267-77
14. Westaway SM. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem 2007;50:2589-96
15. Brito R, Sheth S, Mukherjea D, et al. TRPV1: a potential drug target for treating various diseases. Cells 2014;3:517-45
16. Gomtsyan A, Bayburt EK, Schmidt RG, et al. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-Activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. J Med Chem 2005;48:744-52
17. Plowright AT, Johnstone C, Kihlberg J, et al. Hypothesis driven drug design: improving quality and effectiveness of the design-make-Test-Analyse cycle. Drug Discov Today 2012;17:56-62
18. Kort ME, Kym PR. TRPV1 antagonists: clinical setbacks and prospects for future development. Prog Med Chem 2012;51:57-70
19. Voight EA, Kort ME. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature. Expert Opin Ther Pat 2010;20:1107-22
20. Xia R, Samad TA, Btesh J, et al. TRPV1 signaling: mechanistic understanding and therapeutic potential. Curr Top Med Chem 2011;11:2180-91
21. Szallasi A, Sheta M. Targeting TRPV1 for pain relief: limits, losers and laurels. Expert Opin Investig Drugs 2012;21:1351-69
22. Kyle DJ, Tafesse L. TRPV1 antagonists: a survey of the patent literature. Expert Opin Ther Pat 2006;16:977-96
23. Abbott Laboratories. TRPV1 antagonists. WO134943; 2012
24. Abbott Laboratories. TRPV1 antagonists. US0245163; 2012
25. Abbott Laboratories. TRPV1 antagonists. WO045401; 2010
26. Abbott Laboratories. TRPV1 antagonists. WO045402; 2010
27. Abbott Laboratories. TRPV1 antagonists. EP2352726; 2011
28. Abbott Laboratories. TRPV1 antagonists. EP2352727; 2011
29. AbbVie, Inc. TRPV1 antagonists. US0345255; 2013
30. AbbVie, Inc. TRPV1 antagonists. WO096223; 2013
31. AbbVie, Inc. TRPV1 antagonists. WO096226; 2013
32. AbbVie, Inc. TRPV1 antagonists. US0172334; 2013
33. AbbVie, Inc. TRPV1 antagonists. EP2688866; 2014
34. AbbVie, Inc. TRPV1 antagonists. US0158067; 2013
35. AbbVie, Inc. Compounds that inhibit TRPV1 and uses thereof. US8815930; 2014
36. Grunenthal GmbH. Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands. WO045447; 2013
37. Grunenthal GmbH. Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands. WO045451; 2013
38. Grunenthal GmbH. Substituted methanesulfonamide derivatives as vanilloid receptor ligands. WO045452; 2013
39. Grunenthal GmbH. Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an O-containing group as vanilloid receptor ligands. WO068461; 2013
40. Grunenthal GmbH. Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an N-containing group as vanilloid receptor ligands. WO068462; 2013
41. Grunenthal GmbH. Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an N-cyclic group as vanilloid receptor ligands. WO068463; 2013
42. Grunenthal GmbH. Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an SO2-containing group as vanilloid receptor ligands. WO068464; 2013
43. Grunenthal GmbH. Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a co-containing group as vanilloid receptor ligands. WO068467; 2013
44. Grunenthal GmbH. Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands. WO127855; 2010
45. Grunenthal GmbH. Substituted phenyllureas and phenylamides as vanilloid receptor ligands. WO127856; 2010
46. Grunenthal GmbH. Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor. WO022487; 2012
47. Grunenthal GmbH. Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands. WO062462; 2012
48. Grunenthal GmbH. Substituted bicyclic carboxamide and urea derivatives as vanilloid receptor ligands. WO062463; 2012
49. Grunenthal GmbH. Substituted phenylureas and phenylamides as vanilloid receptor ligands. EP2427435; 2012
50. Grunenthal GmbH. Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands. EP2427436; 2012
51. Grunenthal GmbH. Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands. WO013815; 2013
52. Grunenthal GmbH. Substituted heterocyclic aza derivatives. WO013817; 2013
53. Grunenthal GmbH. Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands. WO013816; 2013
54. Grunenthal GmbH. Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands. US8765733; 2014
55. Japan Tobacco, Inc. 3-Aminobenzamide compounds and vanilloid receptor subtype 1 (VR1) inhibitors. US0115827; 2012
56. Japan Tobacco, Inc. 3, 4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity. US0212952; 2011
57. Palazzo E, Luongo L, de Novellis V, et al. Moving towards supraspinal TRPV1 receptors for chronic pain relief. Mol Pain 2010;6:66 in brain.
58. Glaxo Group Ltd. Imidazo [1, 2-A] pyridine and pyrazolo [1, 5-A] pyridine derivatives as trpv1 antagonists. WO045729; 2012
59. Glaxo Group Ltd. N-cyclobutylimidazopyridine or-pyrazolopyridine carboxamides as trpv1 antagonists. WO072512; 2012
60. Glaxo Group Ltd. N-cyclobutylimidazopyridine-methylamine as trpv1 antagonists. WO139963; 2012
61. Glaxo Group Ltd. N-cyclobutylimidazopyridine-methylamine as TRPV1 antagonists. US8754101; 2014
62. Purdue Pharma L.P., Shionogi & Co. Ltd. TRPV1 antagonists including dihydroxy substituent and uses thereof. WO176061; 2012
63. Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof. WO021276; 2013
64. Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands. US8703962; 2014
65. Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands. US8759362; 2014
66. Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof. US8889690; 2014
67. Sun, Qun. Compounds as TRPV1 blockers, pharmaceutical compositions and medical uses thereof. WO038662; 2011
68. Sun, Qun. Compounds as TRVP1 blockers, pharmaceutical compositions and medical uses thereof. US0184509; 2012
69. Purdue Pharma L.P. Therapeutic agents useful for treating pain. US8637548; 2014
70. Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof. WO162409; 2011
71. Kurose, Noriyuki. Compounds having TRPV1 antagonistic activity and uses thereof. US0123239; 2013
72. PharmEste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion. EP2377850; 2011
73. PharmEste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion. WO120604; 2011
74. Sanofi-Aventis. Tricyclic N-heteroarylcarboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use. US8288376; 2012
75. Sanofi. N-(amino-heteroaryl)-1Hpyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy. US8716272; 2014
76. Sanofi. N-(amino-heteroaryl)-1Hpyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy. US8716273; 2014
77. Novartis AG. Quinazolinone derivatives useful as vanilloid antagonists. EP2387440; 2011
78. Novartis AG. Quinazolinone derivatives useful as vanilloid antagonists. US0184571; 2012
79. Daewoong Pharmaceuticals Co., Ltd. Novel pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof. WO050380; 2012
80. Xention Ltd. Tetrahydro-naphthalene derivatives. US8173841; 2012
81. Amorepacific Corp. Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same. US0152318; 2011
82. Amorepacific Corp. Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same. EP2307394; 2011
83. Janssen Pharmaceutica NV. Tetrahydropyrimidoazepines as modulators of TRPV1. US8673895; 2014
84. Janssen Pharmaceutica NV. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1. US8637527; 2014
85. University of Utah Research Foundation. Antagonists of TRPV1 receptor. WO149218; 2012
86. University of Utah Research Foundation. Antagonists of TRPV1 receptor. US0121168; 2014
87. SNU R&DB Foundation. Novel TRPV1 inhibitory peptide and anti-Aging or antiwrinkle composition for skin comprising same. WO137505; 2013
88. SNU R&DB Foundation. Novel TRPV1 inhibitory peptides and composition for skin-Aging protection or wrinkle improvement comprising the same. US0243711; 2013
89. Korea Food Research Institute, SNU R & DB Foundation. Pharmaceutical composition for preventing/treating TRPV1 activity-related and inflammation-related diseases or conditions containing maillard peptide separated from well-Aged traditional soy sauce as active ingredient. US8653032; 2014
90. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 2009;31:206-19
91. Trevisani M, Gatti R. TRPV1 antagonists as analgesic agents. Open Pain J 2013;6:108-18
92. Melnikova I. Pain market. Nat Rev Drug Discov 2010;9:589-90
93. Chizh BA, O'Donnell MB, Napolitano A, et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007;132:132-41
94. Chizh BA, Sang CN. Use of sensory methods for detecting target engagement in clinical trials of new analgesics. Neurotherapeutics 2009;6:749-54
95. Lehto SG, Tamir R, Deng H, et al. Antihyperalgesic effects of (R, E)-N-(2-hydroxy-2, 3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl) phenyl)-Acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008;326:218-29
96. Reilly RM, McDonald HA, Puttfarcken PS, et al. Pharmacology of modalityspecific transient receptor potential vanilloid-1 antagonists that do not alter body temperature. J Pharmacol Exp Ther 2012;342:416-28
97. Brederson JD, Kym PR, Szallasi A. Targeting TRP channels for pain relief. Eur J Pharmacol 2013;716:61-76
98. Nash MS, McIntyre P, Groarke A, et al. 7-Tert-Butyl-6-(4-chloro-phenyl)-2-Thioxo-2, 3-dihydro-1H-pyrido[2, 3-d] pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity. J Pharmacol Exp Ther 2012;342:389-98
99. Nussinov R, Tsai CJ. Unraveling structural mechanisms of allosteric drug action. Trends Pharmacol Sci 2014;35:256-64
100. Gabizon R, Friedler A. Allosteric modulation of protein oligomerization: an emerging approach to drug design. Front Chem 2014;2:9
101. Lee Y, Choi S, Hyeon C. Mapping the intramolecular signal transduction of G-protein coupled receptors. Proteins 2014;82:727-43
102. Lee Y, Jeong LS, Choi S, et al. Link between allosteric signal transduction and functional dynamics in a multisubunit enzyme: S-Adenosylhomocysteine hydrolase. J Am Chem Soc 2011;133:19807-15
103. Lee Y, Choi S, Hyeon C. Communication over the network of binary switches regulates the activation of A2A adenosine receptor. PLOS Comput Biol 2014;In press
104. Maksay G. Allostery in pharmacology: thermodynamics, evolution and design. Prog Biophys Mol Biol 2011;106:463-73